Sanara Medtech Stock Performance
| SMTI Stock | USD 35.91 0.71 1.94% |
Sanara Medtech has a performance score of 2 on a scale of 0 to 100. The entity has a beta of 1.42, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sanara Medtech will likely underperform. Sanara Medtech right now has a risk of 3.0%. Please validate Sanara Medtech skewness, and the relationship between the value at risk and day median price , to decide if Sanara Medtech will be following its existing price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Sanara Medtech are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong basic indicators, Sanara Medtech is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return 1.78 | Five Day Return 2.03 | Year To Date Return (10.55) | Ten Year Return 510.33 | All Time Return (87.79) |
Last Split Factor 1:100 | Dividend Date 2019-05-10 | Last Split Date 2019-05-10 |
1 | Sanara MedTechs investors will be pleased with their solid 259 percent return over the last five years | 09/24/2024 |
2 | Acquisition by Ortwein Sara N of 3440 shares of Sanara Medtech subject to Rule 16b-3 | 10/03/2024 |
3 | Insider Trading | 10/04/2024 |
4 | Sanara MedTech Inc. Announces Changes to Its Board of Directors | 10/07/2024 |
5 | Sanara MedTech Inc Stock Price Up 4.87 percent on Oct 18 | 10/18/2024 |
6 | Sanara MedTech Inc. insiders have significant skin in the game with 30 percent ownership | 11/04/2024 |
7 | Acquisition by Morrison Christopher A. of 7135 shares of Sanara Medtech subject to Rule 16b-3 | 11/07/2024 |
8 | Sanara MedTech Inc Q3 2024 Everything You Need To Know Ahead Of Earnings | 11/11/2024 |
9 | Sanara MedTech Inc. Q3 2024 Earnings Call Transcript | 11/14/2024 |
10 | US44.00 Thats What Analysts Think Sanara MedTech Inc. Is Worth After Its Latest Results | 11/15/2024 |
11 | Sanara MedTech to Present at the Piper Sandler 36th Annual Healthcare Conference on December 4th | 11/25/2024 |
12 | Acquisition by Ortwein Sara N of 4799 shares of Sanara Medtech subject to Rule 16b-3 | 12/06/2024 |
| Begin Period Cash Flow | 9 M |
Sanara |
Sanara Medtech Relative Risk vs. Return Landscape
If you would invest 3,468 in Sanara Medtech on September 12, 2024 and sell it today you would earn a total of 123.00 from holding Sanara Medtech or generate 3.55% return on investment over 90 days. Sanara Medtech is currently generating 0.0981% in daily expected returns and assumes 2.9963% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Sanara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sanara Medtech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sanara Medtech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sanara Medtech, and traders can use it to determine the average amount a Sanara Medtech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0327
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | SMTI | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.0 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.1 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Sanara Medtech is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sanara Medtech by adding it to a well-diversified portfolio.
Sanara Medtech Fundamentals Growth
Sanara Stock prices reflect investors' perceptions of the future prospects and financial health of Sanara Medtech, and Sanara Medtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sanara Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0508 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 330.15 M | ||||
| Shares Outstanding | 8.74 M | ||||
| Price To Book | 7.91 X | ||||
| Price To Sales | 4.10 X | ||||
| Revenue | 64.99 M | ||||
| Gross Profit | 39.48 M | ||||
| EBITDA | (289.1 K) | ||||
| Net Income | (4.3 M) | ||||
| Cash And Equivalents | 12.68 M | ||||
| Cash Per Share | 1.53 X | ||||
| Total Debt | 11.79 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.86 X | ||||
| Book Value Per Share | 4.55 X | ||||
| Cash Flow From Operations | (3.25 M) | ||||
| Earnings Per Share | (0.99) X | ||||
| Market Capitalization | 320.1 M | ||||
| Total Asset | 73.87 M | ||||
| Retained Earnings | (28.04 M) | ||||
| Working Capital | 5.24 M | ||||
About Sanara Medtech Performance
By evaluating Sanara Medtech's fundamental ratios, stakeholders can gain valuable insights into Sanara Medtech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sanara Medtech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sanara Medtech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 219.28 | 349.66 | |
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.07) | (0.07) | |
| Return On Assets | (0.06) | (0.06) | |
| Return On Equity | (0.10) | (0.10) |
Things to note about Sanara Medtech performance evaluation
Checking the ongoing alerts about Sanara Medtech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sanara Medtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 64.99 M. Net Loss for the year was (4.3 M) with profit before overhead, payroll, taxes, and interest of 39.48 M. | |
| Sanara Medtech currently holds about 12.68 M in cash with (3.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.53. | |
| Sanara Medtech has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Sanara MedTech to Present at the Piper Sandler 36th Annual Healthcare Conference on December 4th |
- Analyzing Sanara Medtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sanara Medtech's stock is overvalued or undervalued compared to its peers.
- Examining Sanara Medtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sanara Medtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sanara Medtech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sanara Medtech's stock. These opinions can provide insight into Sanara Medtech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sanara Stock analysis
When running Sanara Medtech's price analysis, check to measure Sanara Medtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanara Medtech is operating at the current time. Most of Sanara Medtech's value examination focuses on studying past and present price action to predict the probability of Sanara Medtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanara Medtech's price. Additionally, you may evaluate how the addition of Sanara Medtech to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |